Those who have tried the drug Kombiglyze XR have had to deal with a number of side effects, and a number of lawsuits have been filed against the manufacturer, AstraZeneca. These lawsuits have accused AstraZeneca of misrepresenting the risks involved with the drug, including heart failure and a higher chance of death.
Heart failure risk
Various diabetes medicines have been linked to heart failure risks. However, scientists are still not sure why these drugs cause the condition. However, effective treatments can help alleviate the symptoms of heart failure.
In the past, patients have been diagnosed with congestive heart failure after taking diabetes drugs. However, new generation diabetes medicines have been marketed as safe. These drugs are known to help the body produce more insulin. However, scientists are concerned that drugs may affect heart rate, increasing the risk of cardiac arrest.
The Food and Drug Administration (FDA) has been investigating potential heart risks with new generation diabetes medicines since 2014. Last year, the agency ordered manufacturers of Kombiglyze XR to add heart failure risks to the drug’s label. This resulted in a review of two large clinical trials involving heart disease patients.
The review looked at the results of the SAVOR and NEJM studies. The FDA decided to add a heart failure warning to the drug’s label, as well as order the makers to add other safety warnings.
The FDA also ordered manufacturers of Onglyza to add new safety warnings to the drug’s label. This resulted in a review of the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) study. This study was conducted by AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb.
The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) study involved over 16,000 participants. This study was funded by AstraZeneca.
According to the FDA, the increase in hospitalizations for congestive heart failure was 27 percent, compared to the rate for patients in the placebo group. The FDA also acknowledged that the all-cause mortality rate rose among study participants.
There are many lawsuits filed against pharmaceutical companies. These lawsuits allege that manufacturers of Onglyza and Kombiglyze XR concealed the fact that the drugs increase the risk of cardiovascular problems.
Victims of the heart failure risks associated with Onglyza may be eligible to file a lawsuit against AstraZeneca Pharmaceuticals LLP, Bristol-Myers Squibb, and others. These lawsuits may result in money damages awarded in settlements.
Taking Kombiglyze XR for diabetes can have side effects. The medication is made up of metformin hydrochloride and saxagliptin. The drugs work to lower blood sugar levels in adults with type 2 diabetes. They are also used to prevent kidney damage (nephropathy) in people with diabetes. They should be taken regularly to achieve the best results.
Kombiglyze XR can have negative effects on the heart. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 14-1 to recommend stronger warnings. It also found that the medication was associated with a higher risk of hospitalization for heart failure. Those taking the medication may need to make some lifestyle changes to lower their risk of heart failure.
The drug may also cause lactic acidosis. This happens when there is a build-up of lactate in the blood. The condition can be deadly. People with heart failure, kidney or liver disease, or severe infections are more susceptible to developing lactic acidosis. Other symptoms of lactic acidosis include muscle pain, slow or irregular heartbeat, and sleepiness.
If you notice any of these symptoms while taking Kombiglyze XR, contact your doctor immediately. If the symptoms persist, you may need to stop using the medication. It is also important to take blood tests to check your kidney function.
Kombiglyze XR may also have adverse effects on the skin. The medication can cause skin infections. If you have a skin rash, you should contact your doctor. You may also experience fluid-filled blisters on your skin. If you have any of these symptoms, you should stop taking the medication. You may also need to stop taking the medication if you are allergic to it.
The drug can also interact with certain medicines. You should avoid taking Kombiglyze XR if you are allergic to saxagliptin. You should also avoid taking Kombiglyze XR with other antidiabetic drugs. Kombiglyze XR should not be used with diabetes medicines, antibiotics, phenothiazines, and alcoholic beverages. You should also keep Kombiglyze XR away from pets and children.
Kombiglyze XR should also be used with caution if you have a history of diabetes. You should also avoid taking the medication with high serum creatinine.
Hundreds of lawsuits have been filed against drug manufacturers over Onglyza and Kombiglyze XR. These lawsuits allege that the drug manufacturers knew about the risks of the drug but failed to warn consumers and physicians. It is a medication for Type 2 diabetes patients that helps control blood sugar levels. It contains the active ingredient saxagliptin, which works by inhibiting a crucial enzyme.
AstraZeneca, BMS, and AZ have been accused of failing to warn consumers and physicians about the risk of heart failure associated with Onglyza and Kombiglyze. These lawsuits claim that the drug manufacturers marketed the drugs as safe and effective, even though they knew that the drug increased the risk of heart failure.
The family of Lillie Ree Gibson filed a lawsuit against AstraZeneca for the death of their daughter. AstraZeneca is one of the largest pharmaceutical companies in the world. It has an estimated annual income of $26 billion.
AstraZeneca was over-promoted and sold Kombiglyze XR. AstraZeneca may be responsible for the deaths of Kombiglyze XR users. The company could also be held liable for the injuries caused by the drug.
Onglyza is a type of prescription drug that is used to control blood sugar levels in Type 2 diabetes patients. It was approved by the FDA in 2009. However, the drug has been linked to heart failure. It may also raise the risk of pancreatitis and thyroid cancer.
The FDA reviewed two clinical trials in patients with heart disease. The results showed that patients taking Onglyza were at a higher risk of hospitalization for heart failure. In response, the FDA changed the warning label on the drug. However, this label was not updated until 2016.
Many people who use Onglyza are now suffering from severe cardiovascular injuries and complications. They may be eligible to file an Onglyza lawsuit for their medical bills and emotional distress. A personal injury attorney may be able to help you get the compensation you deserve.
The federal MDL (multidistrict litigation) allows for coordinated pretrial proceedings and discovery. Currently, more than 200 Kombiglyze XR and Onglyza lawsuits are pending in federal courts.
Complaints filed against AstraZeneca Pharmaceuticals
Hundreds of complaints filed against AstraZeneca Pharmaceuticals in Kombiglyze XR Lawsuit allege that the drug company failed to warn consumers of the risks of heart failure. These lawsuits allege that AstraZeneca did not perform adequate testing and failed to follow the recommendations of the FDA in 2008.
AstraZeneca Pharmaceuticals LP has been involved in numerous legal proceedings in the US and elsewhere, and is currently defending numerous lawsuits involving allegations of heart failure. The company is also involved in investigations related to its intellectual property rights. AstraZeneca is also involved in investigations related to antitrust law and commercial disputes.
Kombiglyze XR, an extended release version of the drug Onglyza, is intended to lower the risk of complications in people with Type 2 diabetes. Its active ingredient is saxagliptin. It is a DPP-4 inhibitor, which lowers the blood glucose levels. Studies have shown that people taking Onglyza are more likely to be hospitalized for heart failure.
Hundreds of plaintiffs have filed lawsuits against AstraZeneca and Bristol-Myers Squibb, and have alleged that the manufacturers failed to warn about the risks of heart failure. Plaintiffs allege that the manufacturers failed to warn medical professionals and the general public about the risks of heart failure, and that the manufacturers should have warned consumers about the risk of heart failure before marketing the drug. The plaintiffs also allege that the manufacturers failed to warn about the risk of death from heart failure.
A lawsuit was filed against AstraZeneca and Bristol-Myers in the U.S. District Court for the Eastern District of Kentucky, and the court consolidated the lawsuits. The court also ordered AstraZeneca and Bristol-Myers to pay plaintiffs’ attorneys’ fees.
Plaintiffs in the lawsuits allege that the manufacturers of Onglyza did not warn the medical community about the risk of heart failure, and that they failed to warn about the risk of death from the drug. A lawsuit against AstraZeneca may allow victims of heart failure to recover compensation for pain and suffering, loss of wages, and medical expenses.
The US Patent and Trademark Office upheld the challenged claims of the ‘186 patent, and has also upheld other claims of AZ patents, including the coated tablet formulation. The patent is scheduled to expire in the US in 2028.